Drug intelligence / Profile preview

FMC4

Development stage: Preclinical
Lead developer: FimmCyte
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

FMC4 is a monoclonal antibody candidate currently in preclinical development by FimmCyte for the treatment of fibro-inflammatory diseases. It is part of a pipeline of non-hormonal, antibody-based therapies designed to target fibrotic tissue directly. FMC4 is specifically in the lead optimization stage, following the company's lead candidate FMC2, which is being developed for endometriosis. The therapy aims to provide a targeted approach to treating fibrotic conditions without the systemic side effects often associated with hormonal treatments.

Beyond the preview

Go deeper on FMC4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FMC4.

Explore the full profile